Le présent document exprime la position adoptée par l'Association des psychiatres du Canada sur les questions éthiques et scientifiques que soulève l'utilisation de placebos dans l'évaluation de nouveaux psychotropes. Selon l'Association, il faut démontrer l'efficacité des nouveaux psychotropes et les comparer aux interventions qui sont actuellement plus efficaces. Les groupes témoins placebos peuvent être indiqués dans certaines circonstances, malgré l'efficacité d'une intervention établie, c.-à-d. dans les situations où les taux de réponse au placebo sont élevés, variables, ou proches des taux de réponse aux traitements efficaces. Les groupes témoins placebos sont également indiqués quand les interventions établies comportent un risque élevé d'effets secondaires ou lorsqu'elles sont efficaces seulement contre certains symptômes d'un trouble.
References
1.
StreinerDL. The ethics of placebo-controlled trials [editorial]. Can J Psychiatry1995;40:165–6.
2.
LapierreYD. Placebo: A potent but misunderstood psychotrope [editorial]. J Psychiatry Neurosci1995;20:173–4.
3.
ShapiroAK. Factors contributing to the placebo effect. Am J Psychiatry1964;18:73–88.
4.
KlermanGL. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull1986;22:25–9.
5.
PrienRF. Methods and models for placebo use in pharmacotherapeutic trials. Psychopharmacol Bull1988;24:4–8.
6.
TempleR.Difficulties in evaluating positive control trials. Proceedings of American Statistical Association; 1983; p 1–7.
7.
GouldAL. Another view of active-controlled controlled trials. Control Clin Trials1991;12:474–85.
8.
FlemingTR. Treatment evaluation in active control studies. Cancer Treatment Reports1987;71:1061–5.
9.
KraemerHC. To increase power in randomized clinical trials without increasing sample size. Psychopharmacol Bull1991;27:217–24.
10.
AddingtonD.The use of placebos in clinical trials for acute schizophrenia. Can J Psychiatry1995;40:171–6.
11.
GrofPAkhterMICampbellMGottfriesCGKhanILapierreYD, and others. Clinical evaluation of psychotropic drugs for psychiatric disorders; principles and proposed guidelines. In: World Health Organization, editor. Vol 2, WHO expert series on biological psychiatry. Seattle: Hogrefe & Huber; 1993. p 28–9.
12.
LeberPD. Hazards of inference: The active control investigation. Epilepsia1989;30:57S–63S.
13.
LeberPD. The future of controlled clinical trials. Psychopharmacol Bull1991;27:3–8.
14.
BialikRJRavindranAVBakishDLapierreYD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci1995;20:265–70.
15.
BrownWA. Predictors of placebo response in depression. Psychopharmacol Bull1988;24:14–7.
16.
MolchoAStanleyM.Antidepressants and suicide risk: Issues of chemical and behavioral toxicity. J Clin Psychopharmacol1992;12(1 Suppl):13S–18S.
17.
KaneJMSchoolerNRMarderSRSimpsonGMCaseyDE. Methods for clinical evaluation of pharmacological treatments of schizophrenia. In: PrienRFRobinsonDF, editors. Clinical evaluation of psychotropic drugs: Principles and guidelines. New York: Raven; 1994. p 345–72.
18.
CarpenterWT. The negative symptom challenge. Arch Gen Psychiatry1992;49:236–7.
19.
AydFJ. A survey of drug induced extrapyramidal reactions. JAMA1961;175:1054–60.
20.
American Psychiatric Association. Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington (DC): American Psychiatric Association; 1992.
21.
GrissoTAppelbaumPS. The MacArthur treatment competence study, III: Abilities of patients to consent to psychiatric medical treatments. Law and Human Behavior1995;19:149–74.
22.
KisslingW.Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand Suppl1994;89:16–24.
23.
RoyDJWilliamsJRDickensBM. Bioethics in Canada. Scarborough (ON): Prentice-Hall; 1994.
24.
BohmD.Wholeness and the implicate order. London: Routledge & Kegan Paul; 1980.
25.
Medical Research Council. Guidelines on research involving human subjects. Minister of Supply and Services, Canada; 1987. p 3–65.
26.
RothmanKJMichelsKB. The continuing unethical use of placebo controls. N Engl J Med1994;331:394–8.
27.
World Medical Association. Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects [abstract]. 1975.
28.
SramekJJCutlerNR. The use of placebo controls. N Engl J Med1995;332:62.
29.
KramerBA. Use of ECT in California, 1977–1983. Am J Psychiatry1984;41:246–53.
30.
BregginPR. Toxic psychiatry. New York: St Martins Press; 1991.
31.
National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects. US Government Printing Office; 1978.
32.
ChafeSM. Legal obligations of physicians to disclose information to patients. Can Med Assoc J1991;144:681–5.
33.
Tri-Council Working Group on Ethics. Code of conduct for research involving humans, draft document. Ottawa: The Medical Research Council of Canada, The Natural Sciences and Engineering Research Council of Canada, and the Social Sciences and Humanities Research Council of Canada; 1996.
34.
YoungSNAnnableL.The use of placebos in psychiatry: A response to the draft document prepared by the Tri-Council Working Group. J Psychiatry Neurosci1996;21:235–8.
